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Immunotherapy seeks to improve the body’s immune response to a tumor. Currently, the
principal mechanisms employed are: (1) to improve an aspect of the immune response
(e.g., T cell activation) and (2) to encourage the targeting of particular antigens. The latter
is typically achieved by exposing the immune system to the antigen in question, in vivo, or
in vitro followed by re-introduction of the primed cells to the body. The clinical relevance
of these approaches has already been demonstrated for solid tumors such as melanoma
and prostate cancer. The central nervous system was previously thought to be immune
privileged. However, we know now that the immune system is highly active in the brain
and interacts with brain tumors. Thus, harnessing and exploiting this interaction repre-
sents an important approach for treating malignant brain tumors. We present a summary
of progress in this area, focusing particularly on immune-checkpoint inhibition, vaccines,
and T cell engineering.
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INTRODUCTION
Patients with cancer are typically immunosuppressed. This
appears to be a survival strategy of the more aggressive tumors and
is in excess of that which would be expected by external factors
such as chemotherapy, malnutrition and steroid use. When dis-
cussing immunotherapy for tumors affecting the nervous system,
the prototype remains glioblastoma (GB, grade IV glioma). This
is the most common malignant primary central nervous system
(CNS) malignancy (1). Aside from developments in the treatment
of systemic metastases to the brain, the use of immunotherapy of
other CNS tumors is at a relatively less developed stage.
An early observation germane to this field was that tumors
may (rarely) resolve following an infection. This phenomenon has
been documented, for example, in locally advanced pancreatic can-
cer (2). Therapeutic applications of this observation began with
William Coley in 1891, when he injected inactivated Streptococ-
cus Pyogenes and Serratia Marcescen into patients with sarcoma
(3). By inducing systemic immune activation, it was hoped that
the immune system would also increase its activity against the
tumor. Indeed, the vaccine did cause tumor regression in some
patients (4). Another relatively non-specific approach, which has
proven to be of clinical value, has been the use of the Bacil-
lus Calmette–Guérin (BCG) vaccine in those affected by bladder
cancer (5).
These early, non-specific approaches suffered from unpre-
dictable clinical responses. The use of genetically modified live
bacteria remains under active investigation, principally Salmonella
(6). In the case of GB, the addition of live bacteria to surgical
wounds in the hopes of triggering local inflammation has proved
controversial (7).
More tumor-specific therapies have been developed, which do
not rely on a generalized immune response. Such approaches have
already proven advantageous in highly immunogenic malignan-
cies such as melanoma (4). Tumor-infiltrating lymphocytes are
well recognized in GB. Studies to date have yielded conflicting data
on the significance of these in relation to patient outcomes (8, 9).
Nonetheless, their very presence makes enhancing their activity
and specificity an attractive goal.
The gravity of GB has been a motivator for novel approaches.
The median survival remains around 15 months and recur-
rence/progression is almost inevitable (10). Current treatment
modalities include surgery, radiation, chemotherapy (temozolo-
mide, bevacizumab, nitrosoureas), and electrical field treatment.
This latter, known as NovoTTF-100A®, uses alternating electric
fields to inhibit cell growth and has almost no side effects apart
from local irritation of skin (11). The use of “targeted”chemother-
apy, usually a single-agent specifically aimed at a particular
cell-signaling pathway, has thus far been disappointing.
We focus on two emerging methods of harnessing the immune
system in the treatment of GB:
• preventing the tumor from evading the immune system.
• exposing the immune system to antigens expressed by the tumor,
thus stimulating it to attack the tumor.
To further illustrate these two points, we provide data from
recently published clinical trials and from abstracts presented at
the 2014 American Society of Clinical Oncology Annual Meeting
(ASCO).
CNS IMMUNOLOGY
The CNS was previously considered as a relatively ‘immune-
privileged’ site. This was thought to reflect, in part, the protec-
tive nature of the blood–brain barrier (BBB). However, we now
know that the CNS has an active and tightly regulated immune
system (12). The circumventricular organs, which lack a BBB,
have the ability to detect infection in the peripheral bloodstream.
Areas with high vascularity, such as the leptomeninges and the
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choroid plexus, may also lead to microglial activation upon detec-
tion of pathogen-associated molecular patterns (PAMPs) in the
bloodstream (13).
Microglia (phagocytic in function) are part of the evolution-
arily older innate immune system. They are concentrated in the
brain’s gray matter and are less numerous in white matter (the
tracts of which may be used by GB to move to new locations)
(14). Aside from the production of pro-inflammatory factors in
the presence of infection, microglia are believed to play a role
in removing neurotoxic debris (e.g., preventing the amyloid-β
accumulation noted in Alzheimer’s disease).
The adaptive arm of the immune system (responsible for
immunologic memory) was thought to be limited in the CNS
due to the lack of lymphatic channels. Instead, cellular waste from
the interstitial fluid is transferred to the CSF for removal via the
glymphatic system. Circulating lymphocytes may be found within
the CNS in their activated form but naïve T cells are essentially
absent (15–17).
However infiltration of lymphocytes, especially T cells, is
increased in patients harboring GB as the BBB becomes disrupted,
suggesting an important interaction between the immune system
and the tumor (18, 19). The tumor responds with a number of
strategies to counteract the immune system. These include down
regulation of major histocompatibility complex (MHC, respon-
sible for presenting antigens) (20), an increase in cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) and programed cell
death protein 1 (PD-1) (21, 22), IL-10 (23), TGF-β (24), and
by damping immune activity by recruiting regulatory T cells
(TRegs) (25).
In addition to the BBB, the blood–tumor barrier must be
overcome. The formation of new blood vessels by the tumor is
often disorganized, with abnormal flow dynamics and immature
pericytes, making recruitment of lymphocytes challenging. Exper-
iments in mice and clinical observation support the view that
immunotherapy is likely to be much less effective as the vasculature
becomes more chaotic (26).
IMMUNE-CHECKPOINTS
Immune-checkpoints prevent excessive immune activation, which
may lead to collateral damage in healthy tissue. GB makes use of
this apparatus to impair nearby T cell functionality. GB induces
a state of chronic antigen exposure, which gradually increases
the expression of immune-checkpoint proteins and culminates
in lymphocytic exhaustion or anergy (27). By overcoming this
habituation, it is hoped that immune-mediated cytotoxicity may
be recovered.
While many proteins involved in this process have been identi-
fied, we focus here on two for which clinical applications have been
developed: CTLA-4 and PD-1. Both are responsible for the down
regulation of T cell activity (28). CTLA-4 is located on cytotoxic
(CD8+) and the two major subsets of helper (CD4+) T cells. This
protein restricts the activity of the T cell (29, 30). The ligand for
CTLA-4 is similar to that of the co-stimulatory receptor CD28,
(a complex of CD80 and CD86). It is thought to be a competitive
agonist at this site (31, 32). T cell activation is inhibited by reducing
both the production of IL-2 and the expression of its receptor, as
well as arresting lymphocytes in the G1 phase of the cell cycle (33).
Additionally, this immune-checkpoint protein has been shown to
enhance the suppressive function of TReg cells (34, 35).
Ipilimumab is an antibody, which inactivates CTLA-4. This
was the first agent focusing on immune-checkpoint blockade
to receive approval from the FDA (36). It is used for patients
with melanoma and has proven to be effective for those with
brain metastases (37). In GB, a similar approach has been ham-
pered by safety concerns. One review of 10 patients demonstrated
that treatment was devoid of significant toxicities in all but 1
patient (38). However, in a subsequent study with five patients,
all experienced auto-immune-related adverse effects (39). This
typically consisted of a rash with colitis and hypothyroidism;
there was also one case each of encephalitis and partial status
epilepticus.
PD-1 expression is induced upon activation of a T cell; it
serves to limit the potentially deleterious activity of lymphocytes
in peripheral tissues. PD-1 has been shown to be expressed by Tregs
and activation of its receptor appears to aid in their proliferation
(40). PD-1 is also expressed by B cells and NK cells (41).
Nivolumab is a therapeutic antibody against PD-1. Is has
proven to be effective when used with ipilimumab in patients with
melanoma (42). There is an ongoing phase III trial comparing
its efficacy with bevacizumab in patients with recurrent glioblas-
toma (NCT02017717). Pembrolizumab is another such antibody.
Its activity in patients with metastatic melanoma depends on the
presence of pre-existing cytotoxic T cells, which are thought to be
deactivated by the tumor (43).
PD-1 binds to a ligand, PD-L1. This latter is up-regulated in
numerous types of cancer (44). However, the use of PD-L1 as
a biomarker for response to therapeutic checkpoint blockade is
complicated by its heterogeneous expression in tumors, complex
signaling networks, and the normal expression found on lympho-
cytes and other cells within the tumor microenvironment. In GB,
expression of PD-L1 has been linked to the loss of the tumor
suppressor PTEN (phosphatase and tensin homolog) and con-
sequently the PI3K–Akt signaling pathway (phosphatidylinositol
3-kinase – protein kinase B a.k.a. Akt) (45). An antibody blocking
PD-L1, MPDL3280A, has shown efficacy in the setting of metasta-
tic bladder cancer in a phase I trial (46). This approach appears
most effective in those patients in whom pre-existing immunity
is suppressed by PD-L1, as evidenced by high levels of PD-L1 and
CTLA-4 expression (47).
A more radical approach to recovery of immune function is that
of bone-marrow transplant. Autologous progenitor cells have been
used in GB to facilitate higher doses of cytotoxic chemotherapy.
However, given the mortality with a complete marrow transplant,
this has not been the subject of a trial. Experience with other
tumor types suggests that this process “resets” the immune system
and thus allows for recovery of cytotoxicity (48).
VACCINES
Current approaches to immunotherapy may be classified as active
or passive (49). “Passive” refers to antibodies to tumor antigens, or
immune-conjugates aimed at targeted drug delivery (50). “Active”
vaccines are intended to stimulate the patient’s own immune
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response. They may be cell-based (e.g., pulsed dendritic cells) or
non-cell based (i.e., heat-shock protein-based vaccines).
PEPTIDE VACCINES
Exposing short protein sequences to the immune system is usually
done with peptides that are presented by HLA-A2 (human leuko-
cyte antigen). This is the most common of the HLA subtypes but is
found in only 50% of Caucasians and 30% of African-Americans.
To overcome this limitation, antigens binding other class I HLAs
have been developed, bringing population coverage to around
70%. Promising proteins from this line of investigation include:
PTPRZ1 (receptor-type tyrosine-protein phosphatase zeta; func-
tion unclear but implicated in directional outgrowth of glioma
cells), SEC61G (Protein transport protein Sec61 subunit gamma;
involved in protein translocation across the endoplasmic retic-
ulum for degradation), TNC (tenascin C; an extracellular gly-
coprotein typically expressed in development/differentiation and
following injury), and EGFR (51).
EGFRvIII is a constitutively active mutant form of the epi-
dermal growth factor receptor, which is present in approximately
33% of GB (52). Its presence is an independent negative prognos-
tic indicator for survival in patients who manage to survive at least
1 year after initial diagnosis (53). A phase II trial was conducted in
order to determine the immunogenicity, progression-free survival
(PFS), and overall survival (OS) in patients who received a peptide-
based vaccine (PEPvIII) targeted at EGFRvIII-expressing GB (54).
Eligibility criteria included: gross total resection, Karnofsky per-
formance status (KPS) ≥80%, and no evidence of progression
after initial chemo-radiation. Immune reactivity after vaccination
was monitored by observation of a delayed-type hypersensitiv-
ity (DTH) reaction to intradermal injections of PEPvIII and
recall antigens. Eighteen patients were enrolled. Median PFS and
OS were 14.2 and 26 months for those vaccinated vs. 6.3 and
15 months for controls. The skin test was performed in 17 patients;
all showed no response prior to vaccination and all but 3 after vac-
cination. Of 14 patients tested, 6 demonstrated a positive humoral
response against PEPvIII. The toxicity profile was deemed safe
with most adverse reactions consisting of cutaneous reactions at
the injection sites. (One patient had a severe allergic reaction). A
phase III trial to confirm these results is ongoing.
HEAT-SHOCK PROTEIN VACCINES
Heat-shock proteins (HSP) are molecular chaperones; they pro-
vide protein stability by facilitating folding and aid in intra-cellular
localization (55). Their activation is induced by adverse environ-
ments such as hypoxia, inflammation, and oxidative stress (56).
Neoplastic cells are constantly exposed to such stressors; they rely
on the HSP for survival.
A vaccine that includes HSP has proved safe and tolerable in a
Phase I study of 12 patients with recurrent GB (57). After vac-
cination, peripheral leukocytes generally showed a response to
HSP-96-bound peptides, as demonstrated by IFN-γ production
(via real-time PCR). Lymphocytic infiltrates expressing IFN-γ
were identified in those undergoing biopsy. Those showing an
immune response to the vaccine showed an increase in median
OS to 47 weeks vs. 16 in those with no response.
In the subsequent phase II trial, 41 patients with gross total
resection of recurrent GB were vaccinated with HSPPC-96 (58).
The median PFS of this cohort was 19.1 weeks with a median OS
of 42.6 weeks. In both studies, the treatment appeared safe and
tolerable.
AUTOLOGOUS VACCINES
These techniques rely on ex vivo modification of the patient’s
immune system or of the tumor itself, followed by re-introduction
of the altered cells. The immune system, particularly cytotoxic T
lymphocytes, may be stimulated with tumor antigens. Neoplas-
tic cells may be irradiated, or altered with viruses, in the hopes
of increasing their immunogenicity and lowering their propensity
for evasion of the immune system (49, 59).
Newcastle disease virus (NDV) combined with autologous
tumor has been used as a vaccine. This virus has been shown to
replicate selectively in neoplastic cells and to possess immunogenic
properties (60). Twenty-three patients had their tumor surgically
resected and incubated with hemagglutinating units of avirulent
NDV. Concurrently, a control group was established, which com-
prised patients receiving standard care with a KPS of ≥60. An
improvement in median PFS and OS was seen by comparison with
controls: 40 weeks vs. 26 and 100 weeks vs. 49, respectively. Signif-
icant DTH skin reactions were noted when vaccinated patients
were tested against irradiated tumor cells, both virus-modified
and unmodified (61).
Autologous formalin-fixed tumor vaccines (AFTV) use fixed
tissue to sensitize T cells to tumor antigens. In a Phase I/IIa trial,
22 newly diagnosed patients with resected GB received AFTV with
concomitant fractionated radiotherapy (62–65). Median PFS and
OS were promising at 7.6 and 19.8 months. Again, the treatment
combination was well tolerated and adverse events were mostly
limited to cutaneous reactions induced by the injection (66).
DENDRITIC-CELL-BASED VACCINES
This process involves obtaining dendritic cells from a patient and
pulsing them with glioma antigens derived from a resection. A
major advantage is that multiple antigens may thus be presented
(49, 67). This is of particular relevance to GB, which is known
to display high intra-tumoral heterogeneity. Evidence of efficacy
has already been established for metastatic prostate cancer with
sipuleucel-T, although those with nervous system metastases were
excluded from the pivotal trials (68).
DCVax-L® is another such dendritic-cell-based vaccine. In a
phase I clinical trial, 23 patients with resected GB had an immuno-
genic lysate prepared from their tumor plus dendritic-cells derived
from peripheral blood mononuclear cells (PBMC). The dendritic
cells were supplemented with granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-4 before exposure to the
lysate. The treatment was safe, tolerable, and without evidence of
dose-limiting toxicity (69). The median PFS and OS were 15.9 and
31.4 months, respectively. A randomized phase III trial is ongoing
(NCT00045968).
This approach is also being explored as a way to target glioma
stem cells, which represent a radioresistant and chemoresistant
subpopulation of cells within a patient’s tumor. In a phase I trial,
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Table 1 | Immunotherapy-based clinical trials for glioblastoma, which are currently recruiting.
Trial name Phase Target
accrual
Therapy Primary outcome Identifier
PEPTIDE-BASED
Phase I/II trial of IMA950 multi-peptide vaccine plus
poly-ICLC in glioblastoma
I/II 16 IMA950 multipeptide based
vaccine/poly-ICLC/temozolomide/
radiotherapy
Safety, tolerability NCT01920191
Safety and efficacy study of SL-701,
a glioma-associated antigen vaccine to treat recurrent
glioblastoma multiforme
I/II 100 SL-701/imiquimod cream
5%/sargramostim 150 mg
Safety, tolerability,
OS, ORR
NCT02078648
GAPVAC Phase I trial in newly diagnosed
glioblastoma patients
I 20 APVAC1 vaccine/poly-ICLC/
GM-CSF
Safety, feasibility,
biological activity
NCT02149225
APVAC2 vaccine/poly-ICLC/
GM-CSF
Phase I study of safety and immunogenicity of
ADU-623
I 38 ADU-623 Safety, tolerability,
immunogenicity
NCT01967758
IMMUNE CHECKPOINT BASED
A randomized study of nivolumab vs. bevacizumab
and a safety study of nivolumab in adult subjects with
recurrent glioblastoma (GBM) (CheckMate 143)
III 260 Nivolumab, bevacizumab,
ipilimumab
Safety, tolerability,
efficacy
NCT02017717
HEAT-SHOCK PROTEIN BASED
Research for immunotherapy of glioblastoma with
autologous heat-shock protein gp96
I 20 gp96 Safety, efficacy NCT02122822
AUTOLOGOUS-BASED
Randomized phase II multicentre study to investigate
efficacy of autologous lymphoid effector cells specific
against tumor-cells (ALECSAT) in patients with
glioblastoma multiform measured compared to
avastin/irinotecan
II 175 ALECSAT/bevacizumab/irinotecan PFS NCT02060955
Pilot study of autologous t cells redirected to
EGFRVIII-With a chimeric antigen receptor in patients
with EGFRVIII + glioblastoma
I 12 CART-EGFRvIII T cells Safety, feasibility NCT02209376
DENDRITIC-CELL BASED
Study of a drug [DCVax®-L] to treat newly diagnosed
GBM brain cancer
III 300 DCVax®-L Efficacy, PFS NCT00045968
A study of ICT-121 dendritic cell vaccine in recurrent
glioblastoma
I 20 ICT-121 DC vaccine Safety, tolerability NCT02049489
Phase I study of a dendritic cell vaccine for patients
with either newly or recurrent glioblastoma
I 40 aDendritic cell vaccination/
temozolomide/radiotherapy
Safety, tolerability NCT02010606
aDendritic cell vaccination±
bevacizumab (for patients previously
treated with bevacizumab)
Dendritic cell vaccine for patients with brain tumors II 60 Autologous tumor lysate-pulsed DC
vaccination± (0.2% resiquimod or
adjuvant poly-ICLC)
Efficacy NCT01204684
Basiliximab in treating patients with newly diagnosed
glioblastoma multiforme undergoing targeted
immunotherapy and temozolomide-caused
lymphopenia (REGULATe)
I 18 RNA-loaded dendritic cell vaccine
(basiliximab)
Safety, efficacy NCT00626483
(Continued)
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Table 1 | Continued
Trial name Phase Target
accrual
Therapy Primary outcome Identifier
Vaccine therapy with or without sirolimus in treating
patients with NY-ESO-1 expressing solid tumors
I 30 DEC-205-NY-ESO-1± sirolimus Safety, tolerability NCT01522820 (not
glioma-specific)
Ph I personalized neoantigen cancer vaccine with
radiotherapy for patients with MGMT unmethylated,
newly diagnosed glioblastoma
I 20 Radiotherapy, personalized
NeoAntigen Vaccine (NeoVax)
Safety, efficacy NCT02287428
Dendritic cell vaccine for malignant glioma and
glioblastoma multiforme in adult and pediatric subjects
I 20 DC vaccination/tumor lysate/
imiquimod
Safety, efficacy NCT01808820
Vaccine therapy and temozolomide in treating patients
with newly diagnosed glioblastoma
I 10 DC vaccination/temozolomide Safety NCT01957956
Dendritic cell vaccine therapy with in situ maturation
in pediatric brain tumors
I 20 DC vaccination/tumor lysate,
imiquimod
Safety NCT01902771
T-CELL BASEDTHERAPY
CAR T cell receptor immunotherapy targeting
EGFRvIII for patients with malignant gliomas
expressing EGFRvIII
I/II 160 Anti-EGFRvIII CAR transduced
PBL/aldesleukin/fludarabine/
cyclophosphamide
Safety, PFS NCT01454596
Cellular immunotherapy study for brain cancer
(alloCTL)
I 15 Alloreactive CTL Safety, efficacy NCT01144247
CMV-specific cytotoxicT lymphocytes expressing CAR
targeting HER2 in patients with GBM (HERT–GBM)
I 18 HER2.CAR CMV-specific CTLs Safety NCT01109095
Therapy: Poly ICLC, an immunostimulant and ligand for the toll-like receptor; composed of carboxymethylcellulose, polyInosinic-polyCytidylic acid, and poly-l-
lysine double-stranded RNA; Sargramostim, recombinant granulocyte–monocyte colony-stimulating factor; GM-CSF, granulocyte–monocyte colony-stimulating factor;
APVAC, activated personalized vaccination; DC, dendritic cell; PBL, peripheral blood lymphocytes; CAR, chimeric antigen receptor; Aldesleukin, recombinant IL-2;
CMV, cytomegalovirus; CTL, cytotoxic T lymphocyte.
Outcomes: OS, overall survival; PFS, progression free survival; ORR, objective response rate.
Retrieved from https:// clinicaltrials.gov/ on 12/18/2014.
17 patients with newly diagnosed GB were given a dendritic-cell-
based vaccine with a combination of glioma stem cell antigens.
This approach (the ICT-107 vaccine) reported a promising median
PFS and OS of 16.9 and 38.4 months, respectively. Interestingly,
five patients who underwent a subsequent resection had a decrease
or absence of cells positive for CD133, a glioma stem cell marker
(70). A phase II trial was initiated with the same vaccine but
despite currently unpublished data demonstrating a significant
increase in PFS, there was no increase in OS (49). A phase III
trial is planned nonetheless. A similar concept has been applied
in the production of a vaccine (ICT-121) that targets CD133-
positive glioma cells (CD 133 is an enrichment marker for cancer
stem cells). A phase I trial involving this vaccine is underway
(NCT02049489).
VIRAL PROTEIN-BASED VACCINES
A variety of studies have identified human cytomegalovirus
(CMV) proteins and nucleic acids in approximately 90–100%
of primary GBs (71–73). Although the role of CMV in the
pathogenesis and progression of GB is not fully understood, the
prevalence of these antigens in tumor cells and relative absence
in normal surrounding tissue provides an important opportu-
nity to develop targeted immunotherapeutics (74). Interestingly,
one patient receiving DCVax-L developed a specific anti-CMV
(anti-pp65) cytotoxic T cell response (75).
To date, immunotherapeutic targeting of CMV has been tried
in a limited number of patients with high-grade gliomas. One case
study describes a patient with recurrent GB who received adoptive
transfer of CMV-specific T cells concurrently with temozolomide,
which resulted in 17 months without disease progression (76).
Recently, a trial involving patients with GB demonstrated that
the transfer of expanded CMV-specific T cells lead to a median
OS of 403 days (vs. historical median OS of 180 days) and 4/10
patients who completed the treatment remained progression-free
during the study period (77). Ongoing trials are assessing the
use of CMV-specific dendritic-cell vaccines (NCT00639639) and
CMV-specific T cells following drug-induced lymphopenia in GB
(NCT00693095). Direct targeting of CMV with valganciclovir
has been the subject of some controversy and is not currently
recommended outside the context of a clinical trial (78).
T CELL ENGINEERING
Adoptive cell transfer using genetically engineered T cells repre-
sents another attractive immunotherapeutic approach to treat-
ing GB. T cells that recognize specific tumor-associated antigens
(TAAs) can be generated by fusing an extracellular binding domain
www.frontiersin.org January 2015 | Volume 5 | Article 12 | 5
Ampie et al. Immunotherapeutic advancements for glioblastoma
(usually derived from a TAA-specific monoclonal antibody) to
the intra-cellular signaling domain of the T cell receptor (TCR)
to form a chimeric antigen receptor (CAR) (79). CAR T cell
activation is MHC-independent and therefore circumvents issues
involving down regulation of HLA class I molecules and defects
in antigen processing that tumors use to evade T cell recognition
(80). These engineered cells are also potentially more useful than
antibody-based immunotherapies because they have the ability
to migrate through blood vessel walls, penetrate solid tumor,
and recruit addition components of the immune response (81).
CARs have been developed for glioma-specific antigens, including
HER2, IL-13Rα2, and EGFRvIII, and have demonstrated potent
antitumor activity with in vivo models (81, 82).
Interestingly, the CARs generated against HER2 in GB
patients, also recognized the CD133+ stem cell populations, that
are thought to contribute to tumor recurrence (80). Mount-
ing evidence that this has led to a number of clinical trials
exploring the safety and effectiveness of CARs against HER2
(NCT01109095), IL-13Rα2 (NCT00730613; NCT01082926), and
EGFRvIII (NCT01454596).
WHAT HAVE WE LEARNED?
Although immunotherapy has been with us for over a century,
we are still in the preliminary stages of refining this therapeutic
approach. Thus far, immune-based treatments have proven to be
relatively safe with minimal toxicities, especially by comparison
with traditional cytotoxic chemotherapy. Currently, it is estimated
that <20% of patients with GB enroll in clinical trials, so increasing
participation would appear to be a clear priority. Given the variety
of methods receiving attention, much of the field is anticipated
to be in phase I and II trials for some years (Table 1). Hence, the
usual caveats apply regarding lack of power, lack of randomization,
and the use of historical controls. In spite of this, the preliminary
survival data have, on the whole, been encouraging.
Using peripheral immune reactivity as a surrogate marker for
disease activity (and thus outcomes) is attractive, in that it may
allow for more rapid development of active agents. In practice, it
has thus far led to mixed results. While some trials link immune
reactivity with a better prognosis, others show no such association
(83). It is hoped that greater standardization and more refined
methods will overcome these difficulties.
Trials to date have studied the effects of immune-checkpoint
inhibitors and vaccines separately. As our knowledge of these treat-
ments increases, we can begin to consider combining both. Such
an approach has already been shown to be efficacious in a murine
model of glioma (84).
Approaches targeting specifically just one antigen have the
drawback that evolution of resistance appears almost inevitable in
those with GB. Such difficulties are well recognized in solid tumors
to which“targeted”approaches have been applied: at least two such
agents are thought to be necessary (to inhibit tumor growth) and
preferably three (85). Those which aim to simulate the immune
system or expose it to a broad range of antigens thus hold greater
promise. As data on the safety of single-agent approaches accrues
and as patents expire, rational multi-agent combinations are likely
to become the norm for most patients.
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